Description

Edwards Lifesciences: Inside the Powerful TAVR Upswing That Could Redefine Lifetime Valve Management!

Edwards Lifesciences delivered a strong first quarter of 2026, with total sales rising 12.7% year over year to $1.65 billion, supported by broad-based growth across TAVR, TMTT and Surgical. Adjusted EPS of $0.78 exceeded expectations, aided by stronger revenue performance and the timing of strategic investments. The company raised full-year 2026 sales growth guidance to 9% to 11% and adjusted EPS guidance to $2.95 to $3.05, reflecting improved operating leverage. However, management also highlighted that the first quarter benefited from an easier prior-year comparison, while the second half of 2026 faces a higher base due to strong performance in the second half of 2025. The TAVR business remains the largest driver for Edwards Lifesciences, with first-quarter sales of $1.2 billion, up 11% year over year. Growth was supported by increased clinical attention on earlier treatment of severe aortic stenosis, long-term SAPIEN durability data, and stable global average selling prices.